Skip to main content
. Author manuscript; available in PMC: 2012 Nov 22.
Published in final edited form as: J Am Coll Cardiol. 2011 Nov 22;58(22):2332–2339. doi: 10.1016/j.jacc.2011.07.048

Figure 3. Results of immunostaining for Cx43.

Figure 3

The Cx43 level which was measured as the ratio of stained area for Cx43 in the field of view to the total field of view was significantly lower in ACE8/8 mouse hearts than in wild-type mouse hearts (18.3 ± 0.6% vs. 5.4 ± 0.7%, P < 0.005). PP1 treatment resulted in a 2-fold increase in the Cx43 level in ACE8/8 mouse hearts (P < 0.005). The result of immunostaining for Cx43 was consistent with the result of western blotting and it confirmed that the improvement in the Cx43 protein level was associated with the increased level of this protein at its site of function, gap junctions. Treatment with PP3, the inactive analog of PP1, did not increase Cx43 level in compare to untreated ACE8/8 mice (5.4 +/-0.7% vs. 6.5 +/-1%, P = NS) (n=4 for all groups).